Cookson Peirce and Co. Inc. bought a new stake in Krystal Biotech, Inc. (NASDAQ: KRYS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fu
Alps Advisors Inc. cut its stake in Krystal Biotech, Inc. (NASDAQ: KRYS) by 23.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commissi
Krystal Biotech maintains a 'Strong Buy' rating, driven by robust VYJUVEK sales and significant pipeline progress. Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, ba
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tu
Principal Financial Group Inc. raised its position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) by 1.4% in the undefined quarter, according to the company in its most recent disclosure with the S
RFIL, BWMX, FET, KRYS and MAMA are five stocks showing sharp recent price strength as markets start 2026 strong.
Krystal Biotech (KRYS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed throug
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Krystal Biotech is upgraded to Strong Buy, driven by Vyjuvek's commercial success and a robust catalyst-rich pipeline. KRYS boasts 96% gross margins, nearly $1B in cash, and a platform poised to deliv
ISSC, AUGO, OWLT, KRYS and IDN are among a select group of stocks showing strong recent price momentum.
On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.
Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 1
Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) has been given an average recommendation of "Buy" by the eleven analysts that are currently covering the stock, MarketBeat.com reports. One analy
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE